肝细胞癌 (HCC) 占肝癌病例的 85%，是癌症死亡的第三大原因。瑞戈非尼是一种多靶点抑制剂，可显着延长索拉非尼治疗失败的 HCC 患者的无进展生存期。然而，限制瑞格非尼临床应用的主要因素之一是毒性。我们利用 Clinical Trials.gov 和 PubMed 收集了瑞戈非尼的临床数据，并对药物的不良反应和机制进行了广泛的分析。接下来，我们提出了适当的管理技术来提高瑞戈非尼的有效性。我们通过瑞戈非尼的临床试验回顾了瑞戈非尼引起的毒性发生的机制和一般管理策略。此外，通过查阅瑞戈非尼等酪氨酸激酶抑制相关文献，通过回顾瑞戈非尼等酪氨酸激酶抑制相关文献，总结了瑞戈非尼毒性发生的机制以及基于机制的干预策略。这是制约瑞戈非尼毒性的首要因素之一。临床运用和联合治疗主要是其毒性反应。为了优化瑞戈非尼治疗方案，进一步了解瑞戈非尼作为多激酶抑制剂的具体毒性机制尤为重要。

Hepatocellular carcinoma (HCC) accounts for 85% of liver cancer cases and is the third leading cause of cancer death. Regorafenib is a multi-target inhibitor that dramatically prolongs progression-free survival in HCC patients who have failed sorafenib therapy. However, one of the primary factors limiting regorafenib's clinical utilization is toxicity. Using Clinical Trials.gov and PubMed, we gathered clinical data on regorafenib and conducted a extensive analysis of the medication's adverse reactions and mechanisms. Next, we suggested suitable management techniques to improve regorafenib's effectiveness.We have reviewed the mechanisms by which regorafenib-induced toxicity occurs and general management strategies through clinical trials of regorafenib. Furthermore, by examining the literature on regorafenib and other tyrosine kinase inhibition, we summarized the mechanics of the onset of regorafenib toxicity and mechanism-based intervention strategies by reviewing the literature related to regorafenib and other tyrosine kinase inhibition.One of the primary factors restricting regorafenib's clinical utilization and combination therapy is its toxicity reactions. To optimize regorafenib treatment regimens, it is especially important to further understand the specific toxicity mechanisms of regorafenib as a multi-kinase inhibitor.